Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

MLA

Cheng-Yu Chang, et al. “Factors Associated with Outcomes of Second-Line Treatment for EGFR-Mutant Non-Small-Cell Lung Cancer Patients after Progression on First- or Second-Generation EGFR-Tyrosine Kinase Inhibitor Treatment.” Frontiers in Oncology, vol. 13, June 2023. EBSCOhost, https://doi.org/10.3389/fonc.2023.1104098.

APA

Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, & Yu-Feng Wei. (2023). Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1104098

Chicago

Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, and Yu-Feng Wei. 2023. “Factors Associated with Outcomes of Second-Line Treatment for EGFR-Mutant Non-Small-Cell Lung Cancer Patients after Progression on First- or Second-Generation EGFR-Tyrosine Kinase Inhibitor Treatment.” Frontiers in Oncology 13 (June). doi:10.3389/fonc.2023.1104098.